IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 6, November 2025
Impact Factor: 7.67

Regulatory Science in Digital Health and Combination Products

Piyush L. Paratane[1], Anand S. Deshmukh[1], M. N Noolvi[1]
[1]Department of RegulatoryAffairs, Shree Dhanvnatary Pharmacy College, Kim (E), Olpad, Surat, Gujarat, India
paratanepiyush@gmail.com & dranandsdeshmukh@gmail.com

Abstract: *Combination goods that incorporate digital health technology (DHTs) are revolutionizing healthcare by facilitating patient involvement, real-time monitoring, and tailored therapeutic interventions. Drug and device components have historically been integrated in combination products, such as auto-injectors, drug-eluting stents, and prefilled syringes, to enhance therapeutic results. Software as a medical device (SaMD), wearable sensors, mobile health apps, and artificial intelligence/machine learning (AI/ML) algorithms are examples of digital components that have been included to construct complex therapeutic ecosystems with broader clinical and regulatory consequences. The lifecycle regulatory factors that are crucial for the secure and efficient supervision of combination goods enabled by digital health are highlighted in this research. Lifecycle management of software and AI/ML components, where frequent updates raise concerns about cybersecurity, interoperability, and regulatory oversight; post-market surveillance, which increasingly depends on real-world data (RWD) and continuous performance monitoring; and pre-market evaluation, where classification, validation, and usability testing are crucial.*

Keywords: *Digital Health Technologies (DHTs), Combination Products, Software as a Medical Device (SaMD), Artificial Intelligence (AI), Machine Learning (ML), Lifecycle Management, Regulatory Science, FDA, EMA, CDSCO, Pre-market Evaluation, Post-market Surveillance, Real-World Evidence (RWE), Cybersecurity, Harmonization, Patient Safety*

I. INTRODUCTION

A vital part of the advancement of regulatory science, digital transformation helps business, healthcare systems, and regulators better assess, track, and ensure the efficacy, safety, and quality of medical products. Regulatory science, which has historically focused on creating instruments, guidelines, and methods for evaluating medications, biologics, and devices, is now incorporating digital technologies like cloud-based platforms, artificial intelligence (AI), machine learning (ML), real-world data (RWD), and digital health technologies (DHTs). These tools improve global harmonization, transparency, and traceability in addition to speeding up decision-making. In compliance with international regulatory norms, the Ministry of Health and the Central Drugs Standard Control Organization (CDSCO) in India are progressively incorporating digital platforms for quality surveillance, pharmacovigilance reporting, and submissions (CDSCO, 2019). Additionally, digitalization facilitates regulatory dependence and convergence initiatives, allowing for cross-jurisdictional harmonization and shared learning.

Through programs like the Digital Health Center of Excellence and its Framework for the Use of Digital Health Technologies in Drug and Biological Product Development, the U.S. Food and Drug Administration (FDA) has placed a strong emphasis on digital innovation (FDA, 2023). These frameworks demonstrate how digital health technologies facilitate clinical trials, remote monitoring, and the creation of real-world evidence (RWE). Examples of these technologies include wearables, mobile health apps, and software as a medical device. Comparably, the European Medicines Agency (EMA) has included digitalization into its Regulatory Science Strategy to 2025, emphasizing the use of digital platforms, big data, and artificial intelligence in pharmacovigilance, evidence production, and lifecycle product management (EMA, 2020).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

Digital innovation and hybrid goods that mix pharmaceutical, biologic, or medical components with devices or software are driving a significant revolution in the healthcare industry. New paradigms in prevention, diagnosis, treatment, and patient monitoring are being made possible by digital health technologies (DHTs), such as wearable sensors, mobile health apps, remote monitoring, AI/ML diagnostic tools, and software-as-a-medical-device (SaMD). In addition, integrative therapies (e.g., drug delivery systems, inhalers, drug-coated stents, etc.) with improved efficacy, patient convenience, or controlled release are being offered by combination products (drug-device, biologic-device, drug-biologic, or drug-device-software).

1.1 Digital Health in Combination Products

Digital health technologies (DHTs), such as wearables, mobile apps, software as a medical device (SaMD), and networked drug-delivery systems, are being included into combination products (drug + device ± software) more and more. Personalized dosing, closed-loop control, real-time monitoring, adherence assistance, and the generation of continuous real-world data (RWD) streams that can assist in clinical and regulatory decision-making are all made possible by these linkages. Therefore, throughout the product lifecycle, regulators and stakeholders need to take into account the quality, safety, and performance of each component (drug/biologic, device hardware, and software), as well as how they interact with one another.

Software as a medical device (SaMD), wearable sensors, mobile health apps, and networked medicine delivery systems are examples of digital health technologies (DHTs) that are revolutionizing traditional combo products. Inhalers, auto-injectors, and drug-eluting stents are examples of integrated drug-device systems that were previously referred to as combination products. However, because of the addition of DHTs, these products are becoming into digitally enabled therapeutic ecosystems. AI-powered SaMD platforms, for instance, can optimize dosage schedules by analyzing continuous physiological data; insulin pens can automatically store previous doses and transmit information to a smartphone; and sensor-equipped smart inhalers may monitor adherence and inhalation technique.

From regulatory science perspective ,there are advantages and disadvantages to this convergence. The medicine or biologic, the device hardware, and the digital software are the discrete components that regulators and stakeholders must evaluate for safety, efficacy, and quality, but also for how they interact over the whole lifespan. For instance, a cybersecurity intrusion could jeopardize patient safety and data privacy, while a malfunction in a connected sensor could impair medication accuracy. The extent of regulatory control may also be called into question if software updates or modifications to machine learning models affect performance after approval. In order to guarantee that digital health-enabled combination products continue to be safe and effective throughout their use, regulatory bodies such as the FDA, EMA, and CDSCO stress the necessity of integrated evaluation frameworks, strong premarket validation, and post-market lifecycle management strategies.

II. MATERIALS AND METHODS

2.1 Study Design

With aspects of a scoping review, this task was carried out as a structured narrative review. Because position statements, white papers, and regulatory guidance documents are not always indexed in traditional academic databases, the design was selected. In order to cover the range of existing regulatory policies and scientific viewpoints on lifecycle management of digital health-enabled combination products, a scoping-style approach enables the incorporation of both peer-reviewed and grey literature sources.

2.2 Conceptual Framework

A lifecycle-regulation paradigm with three crucial stages was selected by the review:

1. Pre-market evaluation and approval: risk management, proof requirements, submission procedures, and classification.
2. Post-market surveillance and monitoring includes regulatory oversight, vigilance reporting, and real-world performance.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

3. Procedures for verifying, recording, and disseminating modifications to software or algorithms are known as software/AI update management.

2.3 Search Stratergy

Search strings combined controlled vocabulary (MeSH) and free-text terms.

2.4 Data Synthesis

1. Comaparative Matrix Approach: Extracted data were organized into a matrix.
2. Thematic coding: Content was qualitatively coded into themes such as classification divergence, AI-update supervision, post-market evidence frameworks.
3. Gap Identification:Cross-jurisdiction inconsistencies were mapped and potential harmonization opportunities were recorded.
4. Evidence Strength grading: Each document was assigned an evidence level (High = official final guidance, Medium = draft/white paper, Low = expert opinion).

2.5 Quality Assurance and bias management

Because official regulatory sources are considered authoritative, bias risk is minimal for factual requirements. For interpretive analyses, triangulation across multiple jurisdictions and reviewers mitigated subjectivity. Grey literature was used only when corroborated by at least one regulator or peer-reviewed source.

2.6 Ethical Considerations

The study used only publicly available documents and did not involve human or animal participants; hence, no ethics-committee approval was required.

III. DISCUSSION

3.1 Lifecycle Considerations in Digital Health Combination Products

The management of digital health-enabled combination goods necessitates a thorough regulatory strategy that includes ongoing supervision of software and AI/ML components as well as pre- and post-market monitoring. These technologies, especially the digital components, are dynamic by nature, unlike traditional medical products. They can change quickly due to algorithmic learning or software updates. Consequently, in order to maintain safety, effectiveness, and quality throughout time while allowing for innovation, regulators must embrace a lifecycle perspective.

3.1.1 Premarket Assessment:

For digital health-enabled combo goods to be proven safe, effective, and dependable, the pre-market phase is essential. These goods are categorized by regulatory bodies according to their principal mode of action (PMOA), which establishes whether the product will be approved through a drug-led, device-led, or biologic-led process. While drug-device combos are governed by the Medical Device Regulation (MDR 2017/745) in the EU and the New Drugs and Clinical Trials Rules (2019) in India, the FDA's Office of Combination Products (OCP) is in charge of this classification in the US.

All components must be validated and verified during the pre-market evaluation. Regulators anticipate that digital components, like software or mobile applications, will adhere to standards for accuracy, compatibility, and functionality. Human aspects engineering and usability are also crucial, particularly for systems that depend on patient participation (e.g., mobile app–linked injectors, smart inhalers). Additionally, digital endpoints that need to be verified for dependability and regulatory approval—like activity data from wearables or adherence tracking metrics—are being incorporated into clinical studies more frequently.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

3.1.2 Post-market Surveillance:

The standard focus of post-market monitoring for combination products is on product performance and adverse occurrences. However, its reach is further expanded by the integration of digital health. Pharmacovigilance and regulatory choices can be supported by the continuous flow of real-world data (RWD) produced by wearable sensors, mobile health apps, and linked devices. To assess therapeutic efficacy in real-world populations or discover safety flags, for example, a smart inhaler may continually record patient adherence data.

Real-world evidence (RWE) is now emphasized by regulators as a useful addition to clinical trial data. Frameworks for including RWE in submissions are being gradually investigated by the FDA, EMA, and CDSCO; nevertheless, problems with data standards, quality, and privacy still exist. Infrastructure for managing software bugs, device recalls, or cybersecurity breaches is also necessary for continuous post-market monitoring in order to ensure prompt patient protection.

3.1.3 Software Updates and AI/ML Lifecycle Management

Overseeing software upgrades and AI/ML-driven features is one of the most distinctive issues in the lifecycle regulation of digital health-enabled goods. Software changes constantly, in contrast to static medication formulations or device designs; regular updates might add new features, fix bugs, or patch security flaws. Every modification could modify the product's performance characteristics, which would raise regulatory concerns about whether re-approval or re-validation is necessary.

For AI/ML-enabled medical devices, the FDA has proposed a Predetermined Change Control Plan (PCCP) that enables manufacturers to pre-specify the kinds of changes they expect and how they would be verified. In a similar vein, the EMA and other organizations are assessing adaptable routes that strike a compromise between patient safety and innovation. Validating adaptable algorithms that continuously learn from new data is a major regulatory science challenge. Although such adaptability increases accuracy, if unmonitored, it runs the danger of unpredictability, bias, or unforeseen safety implications. Therefore, lifecycle regulatory frameworks need to guarantee AI-driven systems' accountability, transparency, and reproducibility.

3.1.4 Cybersecurity and Data Integrity

Cybersecurity has emerged as a key issue in digital combination product lifecycle management. Vulnerabilities in linked systems can put patients at risk for anything from data breaches to potentially fatal device manipulation as vital health information is transferred between patients, devices, and cloud platforms. For instance, a hacker-prone insulin pump may administer incorrect dosages, so posing a direct risk to patient safety.

Manufacturers must now include cybersecurity risk management into all aspects of the product lifecycle, including post-market patch management, encryption mechanisms, and secure design, according to regulators. The FDA has released guidelines on cybersecurity in medical devices, stressing the importance of ongoing monitoring and aggressive risk mitigation. The significance of data integrity and interoperability is also emphasized by the EMA and CDSCO, which guarantee correct and secure data interchange between digital components across platforms. Cybersecurity is now a fundamental necessity for lifecycle assurance of digitally connected combination products, not an afterthought, according to regulatory scientists.

3.2 Global Regulatory Perspectives

The regulation of combination goods enabled by digital health is complicated because it must take into account fast developing digital technologies like software, AI/ML, and linked systems in addition to the integration of medications, devices, and biologics. Classification, approval, and lifecycle management have been approached differently by various regulatory bodies. The views of the Central Drugs Standard Control Organization (CDSCO, India), the European Medicines Agency (EMA), and the U.S. Food and Drug Administration (FDA) are summarized in this section.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 6, November 2025
Impact Factor: 7.67

3.2.1 United States (FDA)

When it comes to developing regulatory frameworks for combination products and digital health technology, the FDA has taken the lead globally. The designation and review process for these goods is managed by the Office of Combination goods (OCP), which uses the principal mode of action (PMOA) to identify whether a product is part of a biologic-led, drug-led, device led regulatory pathway.

The FDA created the Digital Health Center of Excellence (DHCoE) to improve oversight of digital health. The DHCoE coordinates policy development and guidance for digital health tools, such as cybersecurity, AI/ML-enabled systems, and software as a medical device (SaMD). Guidelines for incorporating DHTs into clinical trials, data gathering, and regulatory submissions are available in the FDA's Framework for the Use of Digital Health Technologies in Drug and Biological Product Development (2023).

The FDA introduced the idea of a Predetermined Change Control Plan (PCCP) and published an AI/ML Action Plan (2021) for AI/ML-enabled devices and software components. This enables manufacturers to foresee and pre-approve specific software modifications without requiring repeated submissions. The FDA encourages manufacturers to use linked devices and digital endpoints for ongoing safety and performance evaluation, emphasizing real-world evidence (RWE) in post-market surveillance.

3.2.2 European Union (EMA / MDR Framework)

Drug-device combinations and digital health goods are mainly regulated in the European Union (EU) by the Medical Device Regulation (MDR 2017/745) and EMA guidelines. In order to ensure that medical devices used in conjunction with medications fulfill more stringent quality, safety, and performance standards, the MDR enhanced requirements for drug-device combinations.

The EMA's Regulatory Science to 2025 Strategy places a strong emphasis on using AI/ML, big data, and empirical evidence into regulatory decision-making. Personalized treatments and more effective clinical trials are thought to be made possible by digital tools. Expectations for pre-market evaluation, including device usability, risk assessment, and human factors engineering, are outlined in the EMA Guideline on Quality Requirements for Drug-Device Combinations (2020).

Software as a medical device (SaMD), however, is subject to MDR regulation in the EU as a stand-alone medical device, regardless of whether it is a component of a combination product. This can make regulatory processes more difficult because producers have to prove that they are meeting both MDR device standards and EMA medicinal product regulations. Product approvals are also being delayed as a result of the strain that MDR implementation issues are currently placing on Europe's regulatory environment.

3.2.3 India (CDSCO / NDCT Rules)

Under the New Drugs and Clinical Trials (NDCT) Rules, 2019, India controls combination products through the Central Drugs Standard Control Organization (CDSCO) and the Ministry of Health and Family Welfare. Depending on whether the medication or device pathway predominates, the regulation classifies combination goods according to PMOA. A prefilled injector pen, for instance, might be considered a drug-led combination, while a device with digital capabilities might be covered by the Medical Devices Rules (2017).

Online pharmacovigilance reporting (PvPI), electronic submissions, and the integration of digital platforms for surveillance are some of the measures India has made to digitize regulatory procedures. Nevertheless, clear guidelines regarding SaMD and digital health technologies (DHTs) in combination products are still being developed. CDSCO has not yet created thorough frameworks for cybersecurity, AI/ML, or post-market software update monitoring, in contrast to FDA and EMA. Rather, it mostly depends on conforming to global norms, like those set forth by the International Medical Device Regulators Forum (IMDRF).

However, there are chances for regulatory innovation in India's quickly expanding digital health ecosystem, which is supported by programs like the Ayushman Bharat Digital Mission (ABDM). For India to maintain its competitiveness in approving and overseeing combination goods provided by digital health, it will be imperative to harmonize with international standards.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

3.3 Challenges and Gaps in Lifecycle Regulation of Digital Health-Enabled Combination Products

Despite the progress made by leading regulatory authorities, significant **scientific, technical, and policy challenges** remain in regulating digital health-enabled combination products. These challenges affect not only the **pre-market approval process** but also **post-market surveillance and lifecycle management**, where digital components—especially software and AI/ML—require constant oversight.

3.3.1 Classification and Regulatory Pathway Ambiguity

Determining the regulatory classification of combination products enabled by digital health is one of the most urgent issues. When digital elements (such AI-based dose modification or remote monitoring) are used for therapeutic or diagnostic purposes, it might be challenging to determine the principal mode of action (PMOA) of combination medicines since they naturally include pharmacological, device, and/or biologic components.

- Although OCP establishes PMOA within the FDA framework, the traditional drug-led vs. device-led classifications are being challenged by the quick development of digital technology.
-The dual compliance requirements under MDR and EMA in the EU lead to approval delays and regulatory overlap.
-Due to a lack of specific SaMD/AI/ML guidelines, classification judgments in India are variable and frequently depend on ad hoc assessments.

This ambiguity results in **uncertainty for manufacturers** regarding development strategies, trial design, and submission requirements.

3.3.2 AI/ML Oversight and Continuous Learning Algorithms

AI/ML gives regulation a dynamic component. Adaptive regulatory models are required because AI models, in contrast to conventional static devices or medications, evolve through continuous learning.

-Although international agencies have not yet adopted comparable frameworks, the FDA has recommended the Predetermined Change Control Plan (PCCP) to regulate software modifications.
-The EU MDR frequently treats adaptive AI/ML systems as static devices and lacks specific provisions for them.
-Silence from regulators regarding AI/ML developments in India delays adoption and increases compliance issues.

The challenge is to establish worldwide standardized guidelines for accepting, tracking, and validating updates powered by AI/ML while maintaining responsibility, transparency, and patient safety.

3.3.3 Cybersecurity and Data Privacy Concerns

There are serious cybersecurity and data privacy threats associated with the combination of mobile health apps and linked devices. Breach can jeopardize product performance and safety in addition to patient confidentiality.

-According to FDA guidance from 2023, manufacturers must include cybersecurity concerns in their pre-market applications.
-Cybersecurity is mentioned in passing in the EU MDR, but GDPR regulates the management of patient data, creating difficult compliance issues.
-Whereas the Digital Personal Data privacy Act (2023) is a positive move, India does not yet have a comprehensive healthcare data privacy law.

3.3.4 Real-World Evidence (RWE) and Post-Market Surveillance

Wearables, sensors, and apps provide enormous volumes of real-world data (RWD) from digital health technology, which can help guide regulatory decision-making. But there are obstacles in turning this into actionable real-world evidence (RWE):

-Absence of defined frameworks for validation, interoperability, and data quality.
-It's unclear if RWE should be used in place of or in addition to conventional clinical trial data.
-The FDA, EMA, and CDSCO have different expectations, which makes it difficult to submit for international studies.

EMA and CDSCO are behind in creating clear pathways for the integration of digital health evidence, but the FDA is more advanced in implementing RWE.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

3.3.5 Harmonization Gaps Across Regulatory Agencies

The absence of uniformity among international authorities is arguably the biggest obstacle.

-The FDA is at the forefront of AI/ML lifecycle management, EMA is focused on quality compliance, and CDSCO is still developing its frameworks.

-Product classifications are inconsistent since SaMD, DHTs, and combination products are defined differently.

-Duplicate regulatory barriers hinder global access and innovation for manufacturers.

Although there are still gaps in the guidelines relevant to digital health, international groups like the International Medical Device Regulators Forum (IMDRF) and ICH are aiming toward greater convergence.

3.3.6 Ethical and Patient-Centric Considerations

Products that support digital health raise moral questions about algorithmic transparency, patient autonomy, and prejudice in AI/ML systems.

-Strong guidelines for guaranteeing equity and inclusion in AI-driven decision-making have not yet been released by regulators.

-There is very little patient involvement in regulatory science, particularly in developing nations like India.

This raises the possibility of digital divide disparities, in which underrepresented groups may not have access to or benefit as much from cutting-edge treatments.

3.4 Future Directions and Recommendations

A forward-thinking, flexible, and internationally harmonized regulatory strategy is required due to the quick development of digital health technologies and their incorporation into combination products. In addition to tackling current issues, regulatory science in the future must also foresee new technological developments. Potential avenues for improving lifetime control of combination goods offered by digital health are delineated in the proposals that follow.

3.4.1 Harmonization of Regulatory Frameworks

Global differences in definitions, classifications, and legal requirements erect needless obstacles to access and innovation. Convergence of regulations is crucial.

-To provide standardized language and international standards for combination goods enabled by digital health, promote cooperation through ICH and IMDRF.

-To cut down on redundant evaluations, create mutual recognition systems for evidence submission (such as RWE and AI/ML validation data).

-Encourage regulatory "work-sharing models," which are akin to EMA-FDA pilot projects, in which authorities collaborate to evaluate products that have digital health components.

3.4.2 Adaptive Regulatory Models for AI/ML

AI/ML demands dynamic monitoring tactics that develop with the product.

-Expand the FDA's Predetermined Change Control Plan (PCCP) idea into a worldwide unified AI/ML lifecycle management framework.

-To guarantee safety and equity, establish specifications for algorithm transparency, bias testing, and recurring re-validation.

-In order to evaluate AI-enabled combo products in controlled settings prior to widespread commercialization, support regulatory "sandboxes."

3.4.3 Strengthening Cybersecurity and Data Privacy

Strong cybersecurity is essential as products enabled by digital health become more and more reliant on connectivity.

-As part of pre-market submissions, require cybersecurity risk assessments.

-Require prompt patching procedures and post-market vulnerability monitoring.

-To guarantee cross-border interoperability and patient trust, harmonize healthcare data governance across jurisdictions (e.g., by harmonizing India's Digital Personal Data Protection Act, the EU GDPR, and the U.S. HIPAA).

ISSN 2581-9429 IJARSCT

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

3.4.4 Leveraging Real-World Evidence (RWE)

By facilitating ongoing assessment of products with digital health capabilities, RWE has the potential to revolutionize regulatory science.

-To guarantee the dependability of RWE, create international standards for data quality and interoperability.

-Promote hybrid trial designs in which the results of traditional clinical trials are supplemented by digital endpoints.

-To improve external validity, enlist international partners in cooperative projects like the FDA's RWE Framework and the EMA's DARWIN EU project.

3.4.5Patient-Centric and Ethical Approaches

Patient engagement must be central to future regulatory science.

-Require manufacturers to incorporate **human factors engineering, usability studies, and patient-reported outcomes (PROs)** in submissions.

-Establish frameworks for **ethical AI**, including transparency of algorithms, informed consent for data use, and safeguards against digital divide inequities.

-Enhance patient involvement in **regulatory decision-making**, ensuring diverse population representation in both clinical trials and digital datasets.

3.4.6 Roadmap for Lifecycle Regulatory Science

A lifecycle-based regulatory framework ought to incorporate the following elements to guarantee safety, effectiveness, and fair access:

-Pre-Market Phase: Cybersecurity risk assessment, adaptive trial designs, usability testing, and early regulatory consultation.

-Clear classification guidelines, standardized submission specifications, and AI/ML change management procedures are all part of the approval phase.

-Post-Market Phase: Proactive cybersecurity updates, worldwide safety data exchange, and ongoing monitoring via RWE.

-Iterative Improvement: Patient-centered feedback loops, adaptive AI frameworks, and regulatory sandboxes.

IV. CONCLUSION

Both remarkable opportunities and previously unheard-of challenges arise from the convergence of digital health and combination products. International regulatory frameworks can promote innovation while guaranteeing patient safety and equity by using a lifecycle-based, harmonized, and flexible regulatory approach. Regulatory science's future depends on its capacity to develop with technology, foreseeing threats, fostering trust, and eventually improving health outcomes globally.

REFERENCES

[1]. U.S. Food and Drug Administration (FDA). Framework for the Use of Digital Health Technologies in Drug and Biological Product Development. 2023.

[2]. U.S. FDA. Digital Health Center of Excellence. 2023.

[3]. European Medicines Agency (EMA). Regulatory Science to 2025: Strategic Reflection. EMA, 2020.

[4]. CDSCO New Drugs and Clinical Trials Rules. Government of India, 2019

[5]. Medical Device Rules (MDR) 2017 https://www.biotech.co.in/sites/default/files/2020-01/MDR17-%20Regulations.pdf

[6]. Medical device rule (2017) https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2022/m_device/Medical%20Devices%20Rules,%202017.pdf